INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
Company to Host Conference Call Today, March 27, at 4:30pm ETBOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune...
Cancer
Single-cell Analysis Market Surges to USD 5.4 Billion by 2033, Propelled by 9.5% CAGR – Verified Market Reports®
The Single-Cell Analysis Market is experiencing robust expansion, driven by surging demand for precision medicine, advancements in genomics, and rising investments...
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed’s Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in...
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
-- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for...
FibroBiologics Announces 2025 Annual Meeting of Stockholders
HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued...
SS Innovations International, Inc. Achieves Another Milestone by Successfully Performing Over 2,000 km North-to-South Robotic Cardiac Telesurgery with its SSi Mantra 3 Surgical Robotic System
The SSI Mantra 3 Surgical Robotic System enabled a seamless connection from SS Innovations headquarters in Gurugram, India to Aster...
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
Reinforces potential of nebokitug to become the first approved drug with disease-modifying activity for PSC--a deadly disorder that currently has...
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
-Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer-...
ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025
GARDEN CITY, NY, March 27, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next...
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer...
Evaxion to announce business update and full year 2024 financial results on April 1, 2025
COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™...
CytoSite Bio Announces Agreement with Lantheus for Granzyme B Targeted PET Imaging Radiotracer for Immunotherapy Assessment
A global collaboration agreement has been signed for the development and commercialization of a Granzyme B-targeted Positron Emission Tomography (PET)...
Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to...
Rarecells Inc. Appoints Dr. Neil Kurtz to Board of Directors
NEW YORK and PARIS, March 26, 2025 /PRNewswire/ -- Rarecells Inc., a pioneering company in liquid biopsy technology, is pleased...
Dr. Lyudmila Sarder Receives Prestigious U.S. Congressional Award for Women’s History Month
"Trailblazing Physician and Advocate Receives U.S. Congressional Award for Advancing Healthcare Access and Community Service Across Central Florida and Beyond"...
Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025
CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage...
Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider
Oslo, Norway, 26 March, 2025 Reference is made to the stock exchange notice published by Zelluna ASA (the "Company") published...
Bluejay Therapeutics Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug (BJT-778) as a Monotherapy Treatment for Chronic Hepatitis D
AZURE-1 will evaluate the efficacy and safety of brelovitug compared to delayed treatmentREDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE)...
Zelluna ASA [ZLNA]: Share capital increase resolution
Oslo, Norway, 26 March, 2025 Reference is made to the stock exchange notice published on 9 January 2025 regarding an...
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference
PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...